Human Chorionic Gonadotropin Levels 0/1-4 Days After Methotrexate Administration For Predicting Ectopic Pregnancy Treatment Success

Ectopic pregnancy is one of the major causes of morbidity and mortality, accounting for 1 to 2% of all pregnancies. With the introduction of recent developments in diagnostic tools, the success rate of medical treatment has increased. The treatment is considered successful, if there is a 15% decline in serum human chorionic gonadotropin (hCG) levels between Days 4 and 7 of follow up in patients receiving single-dose methotrexate (MTX) treatment. In the present study, we aimed to determine whether the change in hCG levels between Days 0 and 4 is useful in predicting treatment success in patients receiving single-dose MTX protocol.A total of 93 patients who were diagnosed with ectopic pre gnancy in our clinic between September 2016 and September 2018 and treated with MTX were retrospectively analyzed. Changes in hCG levels between Days 0/1-4 and 4-7 were calculated.The overall success rate of single-dose MTX treatment was found to be 71.6%. A total of 50 patients of the success group had decreased hCG levels on Day 4, while only 18 patients of the success group had increased hCG levels on Day 4. Using the cut -off value for hCG change between Days 1 and 4, a decrease of 16.1% in hCG levels was found to be the strongest predictor of treatment success. The sensitivity, specificity, and positive predictive value of this cut-off value were 89.7%, 64%, and 87.1%, respectively. In conclusion, early changes in hCG levels may be useful in the follow-up of the treatment success.

PDF

___

Hajenius PJ, Mol F, Mol BW, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2007 10.1002/14651858.CD000324.

Berg CJ, Callaghan WM, Henderson Z, et al. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010; 116: 1302-1309.

Creanga AA, Shapiro-Mendoza CK, Bish CL, Zane S, Berg CJ, Callaghan W.M. Trends in ectopic pregnancy mortality in the United States: 1980-2007. Obstet. Gynecol 2011; 117: 837-843.

Zane SB, Kieke BA, Kendrick JS, Bruce C. Surveillance in a time of changing health care practices: estimating ectopic pregnancy incidence in the United States. Matern. Child Health J 2002; 6: 227-236.

Westaby DT, Wu O, Duncan WC, Critchley HO, Tong S, Horne AW. Has increased clinical experience with methotrexate reduced the direct costs of medical management of ectopic pregnancy compared to surgery?. BMC Pregnancy Childbirth 2012; 12: 98.

Levin G, Dior U, Shushan A, Gilad R, Benshushan A, Rottenstreich A. Early prediction of the success of methotrexate treatment success by 24-hour pretreatment increment in HCG and day 1-4 change in HCGReprod Biomed Online 2019; 39: 149-154.

Yang C, Cai J, Geng Y, Gao Y. Multiple-dose and double-dose versus single-dose administration of methotrexate for the treatment of ectopic pregnancy: a systematic review and meta-analysis. Reprod. Biomed. Online 2017; 34: 383-391.

Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatmentof ectopic pregnancy.Obstet Gynecol 1991; 77: 754-757.

Kirk E, Condous G, Van Calster B, et al. A validation of the most commonly used protocol topredict the success of single-dose methotrexate in the treatment ofectopic pregnancy.Hum Reprod 2007; 22: 858-863.

Stovall TG, Ling FW. Single-dose methotrexate: An expanded clinical trial. Am J Obstet Gynecol 1993; 168: 1759-1765.

Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: A meta-analysis comparing “single dose” and “multidose” regimens. Obstet Gynecol 2003; 101: 778-784.

Lipscomb GH, Givens VM, Meyer NL, Bran D. Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy. Am J Obstet Gynecol 2005; 192: 1844-1848.

Kirk E, Condous G, Bourne T. The non-surgical management of ectopic pregnancy. Ultrasound Obstet Gynecol 2006; 27: 91-100.

Skubisz MM, Dutton P, Duncan WC, Horne AW, Tong S. Using a decline in serum hCG between days 0-4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study. BMC Pregnancy Childbirth 2013; 13: 30.

Wong L, Fung LWY, Cheung CW, Lao TT. Trends in serum human chorionic gonadotropin levels 0-4 days after methotrexate administration for predicting tubal ectopic pregnancy treatment success. Int J Gynaecol Obstet 2018; 141: 245-249. Practice Committee of the American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion.Fertil Steril 2013; 100: 638-644. Doubilet PM.Ultrasound evaluation of the first trimester. Radiol Clin N Am 2014; 52: 1191-1199.

Barnhart KT, SammelMD, Rinaudo PF, Zhou L, Hummel AC, GuoW. Symptomatic patients with an early viable intrauterine pregnancy:HCG curves redefined. Obstet Gynecol 2004; 104: 50-55.

Mehta TS, Levine D, Beckwith B. Treatment of ectopic pregnancy: is a human chorionic gonadotropin level of 2000 mIU/mL a reasonable threshold? Radiology 1997; 205: 569-573. 20. Nguyen Q, Kapitz M, Downes K, Silva C. Are early human chorionic gonadotropin levels after methotrexate therapy a predictor of response in ectopic pregnancy?Am J Obstet Gynecol 2010; 202: 630: 1-5.

Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unrup-tured ectopic pregnancy.Fertil Steril 1989; 51: 435-438. Lipscomb GH, Givens VA, Meyer NL, Bran D. Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy.Fertil Steril 2004; 81: 1221-1224. Agostini A, Blanc K, Ronda I, Romain F, Capelle M, Blanc B. Prognostic value of human chorionic gonadotropin changes after methotrexate injection for ectopic pregnancy.Fertil Steril 2007; 88: 504-506.

Bottin P, Gnisci A, Crochet P, et al. Prognostic value of early hCG changes after methotrexate injection for ectopic pregnancy. Gynecologie, Obstetrique and Fertilite 2014; 42: 3-7.

Skubisz MM, Lee J, Wallace EM, Tonga S. Decline in βhCG levels between days 0 and 4 after a single dose of methotrexate for ectopic pregnancy predicts treatment success: a retrospective cohort study. BJOG 2012; 119: 123.

Kanmaz AGK, Hamdi İnan A, Beyan E, Budak A.Various BhCG monitoring protocols for predicting the success of single-dose methotrexate in the treatment of ectopic pregnancy. J Obstet Gynaecol 2019; 39: 811-815.

Şükür YE, Koyuncu K, Seval MM, Çetinkaya E, Dökmeci F. Comparison of alternative βhCG follow-up protocols after single-dose methotrexate therapy for tubal ectopic pregnancy. Arch Gynecol Obstet 2017; 296: 1161-1165.

Girija S, Manjunath AP, Salahudin A et al.Role of day 4 HCG as an early predictor of success after methotrexate therapy for ectopic pregnancies.Eur J Obstet Gynecol Reprod Biol 2017; 215: 230-233.

Mashiach R, Kislev I, Gilboa D, et al. Significant increase in serum hCG levels following methotrexate therapy is associated with lower treatment success rates in ectopic pregnancy patients. Eur J Obstet Gynecol Reprod Biol 2018; 231: 188-191.

Gabbur N, Sherer DM, Hellmann M, Abdelmalek E, Phillip P, Abulafia O. Do serum β-human chorionic gonadotropin levels on day 4 following methotraxate treatment of patients with ectopic pregnancy predict successful single dose therapy?. Am J Perinatol 2006; 23: 193-196.

Cohen A, Bibi G, Almog B, Tsafrir Z, Levin I. Second-dose methotrexate in ectopic pregnancies: the role of beta human Chorionic gonadotropin. Fertility sterility 2014; 102: 1646-1649.